Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Artificial Intelligence (AI) can be a great tool in diagnosing and management of atopic dermatitis -- a chronic skin condition -- leading to more accurate, early, and standardised identification ...

In addition, 0.7% reported pruritus, and 0.5% reported ... that developed during his second treatment period (the site of application was the hip); the rash lasted 10 days and resolved without ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.

Treatment-related adverse events (TRAEs ... common in the nivolumab-ipilimumab arm than in the chemotherapy arm included pruritus (22% and 5%), hypothyroidism (16% and 0%), rash (10% and 8%), alanine ...

Image: Adobe Stock The release states the drug has been approved for subcutaneous injection in the treatment of renal ... musculoskeletal pain, pruritus, rash and cough. The release states that ...

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...